Natalizumab (Tysabri) and its biosimilar copy Tyruko appear equally effective at reducing relapses and brain inflammation in multiple sclerosis patients, according to a 2026 systematic review of 42 studies involving 22,409 people. However, Gram Research analysis found that both drugs cost significantly more than other available MS treatments while providing similar or worse health outcomes, making them less cost-effective options for highly active relapsing-remitting MS despite their clinical effectiveness.

Researchers compared natalizumab (Tysabri) and its cheaper copy, Tyruko, for treating aggressive multiple sclerosis that doesn’t respond to other medicines. According to Gram Research analysis of 42 studies involving over 22,000 people, both drugs appear equally effective at reducing relapses and brain lesions. However, the economic analysis found that natalizumab and Tyruko are more expensive than other available treatments without providing better results. The study highlights a gap: no research has directly tested these drugs in patients with the most severe, treatment-resistant form of MS, so doctors still need more evidence before making treatment decisions.

Key Statistics

A 2026 systematic review of 42 studies with 22,409 participants found no meaningful difference between natalizumab and its biosimilar Tyruko for reducing relapses, with a rate ratio of 0.65 (95% credible interval 0.33 to 1.23), indicating similar effectiveness in relapsing-remitting multiple sclerosis.

According to the 2026 health technology assessment, natalizumab and Tyruko had higher costs than other MS treatments but provided similar or worse quality-adjusted life-years, with the only exception being ocrelizumab, which showed lower net benefits at the 20,000 to 30,000 pounds per quality-adjusted life-year threshold.

The 2026 systematic review found that among 42 studies with over 22,000 participants, only four studies evaluated natalizumab or Tyruko, and none provided direct evidence of effectiveness in patients with highly active relapsing-remitting multiple sclerosis.

In the 2026 analysis of highly active relapsing-remitting MS, all interventions except interferon beta-1a were associated with reduced relapse risk compared to placebo across six studies and seven interventions.

The Quick Take

  • What they studied: Whether natalizumab (Tysabri) and its biosimilar copy (Tyruko) work better than other MS medicines for patients whose disease keeps getting worse despite treatment.
  • Who participated: Over 22,000 people across 42 different studies, mostly with relapsing-remitting MS (the most common type). Only a small number had the severe, treatment-resistant form called highly active relapsing-remitting MS.
  • Key finding: Natalizumab and Tyruko appear equally effective at reducing relapses and brain inflammation compared to other MS drugs, but they cost significantly more without providing better health outcomes.
  • What it means for you: If you have aggressive MS that doesn’t respond to first-line treatments, these drugs may help, but they’re not necessarily better than cheaper alternatives. Talk with your neurologist about which option makes sense for your situation and insurance coverage.

The Research Details

Researchers conducted a systematic review, meaning they searched medical databases through April 2024 and collected all available studies comparing different MS treatments. They included 42 studies with data from 22,409 participants. Most studies followed patients for 24 months on average, tracking how many relapses they had, changes in brain scans, and side effects. The researchers then used statistical methods called network meta-analysis to compare all the treatments against each other, even when studies didn’t directly test them head-to-head. Finally, they built an economic model to calculate whether the benefits justified the costs for the UK’s National Health Service.

This approach is important because no single study has directly tested natalizumab or Tyruko in patients with the most severe form of MS. By combining data from many studies and using economic modeling, researchers could estimate how well these drugs might work and whether they represent good value. This type of analysis helps healthcare systems decide which medicines to fund when direct evidence is limited.

The study is comprehensive, including over 22,000 participants across multiple countries and decades of research. However, a major limitation is that only four studies actually tested natalizumab or Tyruko, and none specifically included patients with highly active relapsing-remitting MS. The researchers had to infer effectiveness based on studies in less severe MS patients. The economic model depends on assumptions about how well these drugs work in the most severe cases, which weren’t directly tested. Results were consistent across different sensitivity analyses, suggesting the findings are fairly robust.

What the Results Show

When comparing natalizumab and Tyruko directly, the researchers found no meaningful difference between them. Both drugs reduced relapses at similar rates, reduced brain lesions seen on MRI scans equally well, and had similar rates of side effects and treatment discontinuation. The rate ratio for relapses was 0.65 (meaning natalizumab reduced relapses by about 35% compared to Tyruko), but the confidence interval was wide (0.33 to 1.23), indicating this difference could easily be due to chance. For brain lesions, the hazard ratios were 1.29 for gadolinium-enhancing lesions and 1.07 for T2-weighted lesions, both showing no meaningful difference. The economic analysis found that natalizumab and Tyruko cost more than other MS treatments while providing similar or worse quality-adjusted life-years, making them less cost-effective choices.

Among other MS drugs tested, several showed benefits for reducing relapses: alemtuzumab, ocrelizumab, cladribine, fingolimod, and peginterferon beta-1a all reduced disease progression compared to placebo. However, fingolimod, glatiramer acetate, and interferon beta drugs were associated with higher treatment discontinuation rates, meaning more patients stopped taking them due to side effects or other reasons. There was little evidence that any treatment improved quality of life compared to others. In the highly active MS subgroup, all treatments except interferon beta-1a reduced relapse risk compared to placebo.

This research aligns with existing knowledge that natalizumab is an effective MS treatment, but it provides new information about its biosimilar copy, Tyruko. Previous studies established natalizumab’s effectiveness in general MS populations. This analysis extends that by suggesting Tyruko works similarly, which is important because biosimilars are cheaper copies of expensive biologic drugs. However, the finding that natalizumab isn’t cost-effective compared to other options challenges some previous assumptions about its role in MS treatment strategies.

The biggest limitation is the lack of direct evidence in highly active relapsing-remitting MS. Researchers had to estimate effectiveness based on studies in less severe patients and then apply those estimates to sicker populations. Only four studies tested natalizumab or Tyruko at all, and none in the target population. The economic model depends heavily on assumptions about treatment effectiveness and costs that may vary by country and healthcare system. Study follow-up periods ranged from 4 to 36 months, with most around 24 months, so long-term effects beyond 2 to 3 years remain unknown. The researchers note that the greatest source of uncertainty in their conclusions is the actual effectiveness of treatments in highly active MS patients.

The Bottom Line

For patients with highly active relapsing-remitting MS that doesn’t respond to first-line treatments, natalizumab and Tyruko appear to be effective options based on indirect evidence. However, they are not the most cost-effective choices compared to alternatives like ocrelizumab or alemtuzumab. Treatment decisions should be individualized based on your specific disease pattern, previous treatment responses, side effect tolerance, and insurance coverage. Confidence level: Moderate for effectiveness (based on indirect evidence), High for cost-effectiveness concerns (based on economic modeling).

This research is most relevant for people with highly active relapsing-remitting MS who have failed at least one other disease-modifying therapy. Neurologists treating aggressive MS should consider this evidence when counseling patients about treatment options. Healthcare administrators and insurance companies should note that while natalizumab and Tyruko are effective, they may not represent the best use of limited healthcare resources compared to other available treatments. Patients should not avoid these drugs if their doctor recommends them, but should discuss cost and alternatives.

Most studies followed patients for about 24 months. Benefits in reducing relapses and brain inflammation typically appear within the first 3 to 6 months of treatment, with continued benefit over the first 1 to 2 years. However, long-term effects beyond 2 to 3 years are not well-studied. Patients should expect to see changes in relapse frequency and MRI findings within 6 to 12 months if the drug is working.

Frequently Asked Questions

Is Tyruko as good as Tysabri for treating aggressive multiple sclerosis?

According to a 2026 systematic review of 42 studies, Tyruko and Tysabri appear equally effective at reducing relapses and brain lesions in MS patients. However, no studies have directly tested either drug in people with highly active relapsing-remitting MS, so effectiveness in the most severe cases remains uncertain.

Why would doctors prescribe Tyruko instead of Tysabri if they work the same?

Tyruko is a biosimilar, meaning it’s a cheaper copy of Tysabri that works the same way. Doctors might recommend it to reduce costs for patients or healthcare systems. However, a 2026 analysis found both drugs are more expensive than other MS treatments without providing better results.

What MS drugs work better than natalizumab for aggressive disease?

According to the 2026 review, ocrelizumab, alemtuzumab, and cladribine all showed good effectiveness for highly active relapsing-remitting MS and were more cost-effective than natalizumab. Your neurologist can help determine which option suits your specific situation.

How long does it take to see if natalizumab is working?

Most studies followed patients for about 24 months. Benefits in reducing relapses typically appear within 3 to 6 months, with continued improvement over the first 1 to 2 years. Discuss with your neurologist what improvement to expect in your specific case.

Are there serious side effects from natalizumab or Tyruko?

The 2026 systematic review of 42 studies found no meaningful differences in serious adverse events between natalizumab, Tyruko, and other MS treatments compared to placebo. However, all MS drugs carry risks, so discuss potential side effects with your doctor before starting treatment.

Want to Apply This Research?

  • Track relapse frequency and severity monthly using a simple log: date of relapse onset, symptoms experienced, duration, and whether you needed hospitalization or steroid treatment. Compare your relapse rate before and after starting treatment to assess effectiveness.
  • Set up monthly reminders to review your relapse log and discuss trends with your neurologist. If you’re on natalizumab or Tyruko, track injection dates and any injection site reactions. Report any new or worsening symptoms immediately, as these drugs require careful monitoring.
  • Maintain a 12-month rolling average of relapses to identify trends. Schedule quarterly check-ins with your neurologist to review this data alongside MRI results. If your relapse rate isn’t improving after 6 months, discuss with your doctor whether the treatment is working or if alternatives should be considered.

This article summarizes research findings and should not replace professional medical advice. Multiple sclerosis is a complex condition requiring individualized treatment decisions made with your neurologist. Treatment choices depend on your specific disease pattern, previous treatments, side effect tolerance, and healthcare coverage. Do not start, stop, or change MS medications without consulting your healthcare provider. If you experience new or worsening symptoms, contact your doctor immediately. This research has limitations, including lack of direct evidence in highly active relapsing-remitting MS patients, so clinical judgment remains essential in treatment decisions.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model. , Health technology assessment (Winchester, England) (2026). PubMed 42579606 | DOI
Topics
natalizumab Tyruko biosimilar multiple sclerosis highly active relapsing-remitting MS MS treatment disease-modifying therapy cost-effectiveness